PATENT ABSTRACTS

cause of neonatal sepsis and meningitis. These antibodies have been found to be protective against lethal challenges of these bacteria, which include group B streptococcus, E. coli, KI, and Neisseria meningitidis group B. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal anitbodies, blood plasma fractions and anti- microbial agents, and the prophylactic and therapeutic use of such compositions in the man- agement of infections, are included.

4 9 7 0 1 ~

M E T H O D F O R I N S E R T I N G F O R E I G N G E N E S I N T O C E L L S

U S I N G P U L S E D R A D I O F R E Q U E N C Y

Donald C Chang assigned to Baylor College of Medicine

Disclosed are an apparatus and a method for the poration and fusion of cells using high-power radiofrequency electrical pulses. The electrodes of the apparatus can be hand held or part of in- tegrated equipment with special containers for cells. The electrodes, which are positioned equi- distant from each other, are attached to a high power function generator. The power function generator can apply a continuous AC electrical field and/or a high-power pulsed radiofrequency electrical field across the electrodes. The alter- nating electrical field induces cell congregation by the process of dielectrophoresis. The high- power pulsed radiofrequency electrical field porates or fuses the cells. The method has the ab- ility to porate or fuse biological cells with a very high efficiency. The method can be used to fuse or porate a variety of cells including animal cells, human cells, plant cells, protoplasts, erythrocyte ghosts, liposomes, vesicles, bacteria and yeasts. The method has the unique ability to porate or fuse cells in very small or very large numbers. During the poration or fusions, a variety of chemical agents including DNA, RNA, anti- bodies, proteins, drugs, molecular probes, hor- mones, growth factors, enzymes, organic chemicals and inorganic chemicals can be in- troduced into these cells. The method can also be used to produce new biological species, to make hybridoma cells which produce animal or human monoclonal antibodies and to insert therapeutic genes into human cells which can be transplanted back into the human body to cure genetic diseases.

123

4970161

H U M A N I N T E R F E R O N - G A M M A

Tetsu Kakutani, Keiji Matsumoto, Hiroyuki Maruyama, Kaku Nakagawa, Shinichi Yokota, Hideo Niwa, Katsuhiro Shinjo, Hajime Kawaharada, Kiyoshi Watanabe, Kakogawa, Japan assigned to Kanegafuchi Kagaku Kogyo Kabushiki Kaisha

A DNA sequence on which a chromosomal DNA sequence coding for human interferon- gamma (HuIFN- gamma) and having a TATA box is ligated to a sequence of a promoter. Cell cultures transformed with said DNA revealed a higher expression of HuIFN- than cell cultures transformed with a DNA which does not have such TATA box. When transformed with said DNA, cell cultures produced HuIFN- gamma in a serum free medium. Transformed cell cultures derived from blood cells of HulFN- gamma resistant human cell-line also could produce HuIFN- gamma.

4970198

A N T I T U M O R A N T I B I O T I C S (LL-E33288 C O M P L E X )

May D Lee, Michael Greenstein, David P Labeda, Amedeo A Fantini assigned to American Cyanamid Company

Antibacterial and antitumor agents designated LL-E33288 complex and their production by new strains of Micromonospora echinospora ssp. calichensis NNRL-15839, NRRL-15975 and NRRL-! 8149, are disclosed.

4970299

M O N O C L O N A L A N T I B O D I E S S E L E C T I V E F O R P R O S T A T E

C A N C E R

Miche Bazinet, Richard J Cote, Lloyd J Old as- signed to Sloan-Kettering Institute for Cancer Research

Four monoclonal antibodies are found which selectively identify prostate cancer. These mono- clonals are therefore useful in diagnosis, dif- ferential diagnosis and treatment of prostate cancer.